Ricci, Caterina
 Distribuzione geografica
Continente #
EU - Europa 726
NA - Nord America 635
AS - Asia 77
AF - Africa 4
SA - Sud America 2
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 1.446
Nazione #
US - Stati Uniti d'America 632
IT - Italia 222
DE - Germania 184
SE - Svezia 99
PL - Polonia 52
FR - Francia 42
CN - Cina 38
IE - Irlanda 34
UA - Ucraina 30
GB - Regno Unito 24
IN - India 12
FI - Finlandia 10
BE - Belgio 9
HK - Hong Kong 8
RU - Federazione Russa 6
IR - Iran 5
KR - Corea 4
RO - Romania 4
AT - Austria 3
CA - Canada 3
NL - Olanda 3
SG - Singapore 3
TR - Turchia 3
VN - Vietnam 3
CI - Costa d'Avorio 2
AU - Australia 1
BR - Brasile 1
CH - Svizzera 1
DK - Danimarca 1
EC - Ecuador 1
EG - Egitto 1
ES - Italia 1
EU - Europa 1
MA - Marocco 1
MO - Macao, regione amministrativa speciale della Cina 1
MT - Malta 1
Totale 1.446
Città #
Chandler 131
Ashburn 79
Warsaw 52
Dublin 34
Ann Arbor 28
New York 28
Milan 27
Jacksonville 25
Rome 24
San Mateo 21
Fairfield 20
Houston 16
Marseille 16
Wilmington 15
Bremen 13
Nürnberg 13
Dearborn 12
Redwood City 12
Nanjing 10
Pescara 10
Woodbridge 10
Boston 9
Cambridge 9
Princeton 9
Brussels 8
Washington 7
Seattle 6
Beijing 5
Busto Arsizio 5
Cattolica 5
Paris 5
Detroit 4
Hong Kong 4
Lancaster 4
Mcallen 4
Munich 4
Pisa 4
Allumiere 3
Amsterdam 3
Asti 3
Baronissi 3
Changsha 3
Chicago 3
Dong Ket 3
Giulianova 3
Helsinki 3
Izmir 3
Jeju City 3
Lawrence 3
London 3
Norwalk 3
San Diego 3
Shenyang 3
Toronto 3
Abidjan 2
Agropoli 2
Andover 2
Augusta 2
Bari 2
Boardman 2
Bucharest 2
Buffalo 2
Chennai 2
Crispano 2
Edinburgh 2
Guidonia Montecelio 2
Hefei 2
Jasper 2
Kunming 2
Lecco 2
Mountain View 2
Nanchang 2
Nave 2
Osimo 2
Paola 2
Scandiano 2
Shanghai 2
Tappahannock 2
Tianjin 2
Vienna 2
Wangels 2
Acton 1
Aquila 1
Ardabil 1
Ariccia 1
Arnsberg 1
Auburn Hills 1
Baton Rouge 1
Cairo 1
Chiswick 1
Chongqing 1
Copenhagen 1
Cupertino 1
Dallas 1
Dunoon 1
Frankfurt am Main 1
Fremont 1
Guidonia 1
Hangzhou 1
Indiana 1
Totale 812
Nome #
Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence 239
NEOPLASIE DELLA VULVA E DELLA VAGINA 220
Quality of life and psychological distress in locally advanced cervical cancer patients administered pre-operative chemoradiotherapy 146
Vascular involvement in inflammatory bowel disease: pathogenesis and clinical aspects. 128
Clinical performance of human papillomavirus E6 and E7 mRNA testing for high-grade lesions of the cervix. 98
Neoadjuvant chemotherapy followed by conization in stage IB2–IIA1 cervical cancer larger than 2 cm: a pilot study 75
Locally Advanced Cervical Cancer in Pregnancy 68
Chemotherapy resistance in epithelial ovarian cancer: Mechanisms and emerging treatments 64
Cancer and Mediterranean Diet: A Review 58
Real-world management of trabectedin/pegylated liposomal doxorubicin in platinum-sensitive recurrent ovarian cancer patients: A national survey 56
Hpv and cytology testing in women undergoing 9-valent hpv opportunistic vaccination: A single-cohort follow up study 55
Health utilities lost and risk factors associated with HPV-induced diseases in men and women: The HPV Italian collaborative study group 44
Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer 42
Intestinal Permeability and Dysbiosis in Female Patients with Recurrent Cystitis: A Pilot Study 27
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 25
Recent progress in the use of pharmacotherapy for endometrial cancer 20
PARP Inhibitors Resistance: Mechanisms and Perspectives 20
Long-term efficacy and safety of human papillomavirus vaccination 20
Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon? 18
Are we facing a new colposcopic practice in the HPV vaccination era? Opportunities, challenges, and new perspectives 17
Advanced and recurrent endometrial cancer: State of the art and future perspectives 14
Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives 13
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 11
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 4
Totale 1.482
Categoria #
all - tutte 5.691
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.691


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201928 0 0 0 0 0 0 0 0 0 5 18 5
2019/2020217 14 26 20 24 21 33 16 13 13 8 18 11
2020/2021181 6 13 5 16 23 5 16 2 17 12 51 15
2021/2022175 17 8 5 12 6 10 3 25 7 18 18 46
2022/2023449 48 56 22 64 21 63 23 30 62 17 30 13
2023/2024241 13 52 24 27 10 47 40 13 9 6 0 0
Totale 1.482